Stockscreener 앱 받기
1.92
2.13%
0.04
시간 외 거래:
1.84
-0.08
-4.17%
전일 마감가:
$1.88
열려 있는:
$1.88
하루 거래량:
388.38K
Relative Volume:
0.94
시가총액:
$187.16M
수익:
$32.38M
순이익/손실:
$-21.64M
주가수익비율:
-7.6281
EPS:
-0.2517
순현금흐름:
$-13.78M
1주 성능:
+0.00%
1개월 성능:
+2.67%
6개월 성능:
-20.99%
1년 성능:
-7.25%
1일 변동 폭
$1.85
$1.95
1주일 범위
$1.85
$2.00
52주 변동 폭
$1.74
$3.59
Stereotaxis Inc Stock (STXS) Company Profile
명칭
Stereotaxis Inc
전화
314-678-6100
주소
4320 Forest Park Avenue, Suite 100, St. Louis, MO
Compare STXS vs ISRG, BDX, MDLN, ALC, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
STXS
Stereotaxis Inc
|
1.92 | 183.26M | 32.38M | -21.64M | -13.78M | -0.2517 |
ISRG
Intuitive Surgical Inc
|
431.87 | 148.77B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
147.51 | 39.44B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
38.55 | 33.19B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
63.78 | 30.25B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
203.79 | 28.83B | 5.54B | 1.52B | 1.74B | 10.37 |
Stereotaxis Inc Stock (STXS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-16 | 개시 | Citizens JMP | Mkt Outperform |
| 2024-01-10 | 개시 | ROTH MKM | Buy |
| 2022-07-12 | 개시 | Aegis Capital | Buy |
| 2022-06-23 | 개시 | B. Riley Securities | Buy |
| 2022-01-05 | 개시 | Craig Hallum | Buy |
| 2022-01-05 | 개시 | Loop Capital | Buy |
| 2021-05-26 | 개시 | Piper Sandler | Overweight |
| 2020-09-08 | 개시 | Northland Capital | Outperform |
| 2020-04-09 | 개시 | Cowen | Outperform |
| 2020-04-07 | 개시 | Lake Street | Buy |
모두보기
Stereotaxis Inc 주식(STXS)의 최신 뉴스
Stereotaxis Inc (STXS) Q1 2026 Earnings Call Highlights: Navigat - GuruFocus
Stereotaxis, Inc. (STXS) Reports Strong Q1 2026 Earnings and Gro - GuruFocus
STXS: Transition to new robotic and catheter platforms drives optimism for double-digit growth in 2026 - TradingView
Is Stereotaxis (STXS) Still 23.2% Undervalued After Q1 2026? EPS - GuruFocus
Stereotaxis Inc. (STXS) Reports Q1 Loss, Lags Revenue Estimates - Yahoo! Finance Canada
Earnings call transcript: Stereotaxis Q1 2026 misses forecasts, stock dips By Investing.com - Investing.com Canada
Stereotaxis Q1 2026 Earnings Call Transcript - Benzinga
Stereotaxis Q1 Loss Narrows, Revenue Falls - marketscreener.com
Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates - The Manila Times
Surgical robotics provider Stereotaxis' Q1 revenue misses analyst estimates - TradingView
STXS: FDA approvals and Robocath deal set stage for growth despite Q1 revenue decline - TradingView
Stereotaxis (NYSE: STXS) Q1 revenue dips as FDA clearances and Robocath deal advance - Stock Titan
Stereotaxis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
TradingKey - TradingKey
Stereotaxis Q1 2026 earnings preview - MSN
Stereotaxis stock up on first US MAGIC procedures post approval - MSN
TD Cowen Maintains Stereotaxis(STXS.US) With Buy Rating, Maintains Target Price $5 - Moomoo
STXS Stereotaxis revenue jumps 20 percent year-over-year to 32.4 million, profitability challenges persist.Market Perform - newser.com
STXS to acquire Robocath to lead in endovascular robotics market - MSN
Stereotaxis to acquire Robocath for up to $45M - MSN
Earnings Preview: Stereotaxis to Report Financial Results Post-market on May 12 - Moomoo
Stereotaxis to acquire Robocath for $20M upfront - MSN
Why Stereotaxis (STXS) Could Be One of the Best Robotics Stocks to Buy Under $30 - Insider Monkey
5 Best Robotics Stocks to Buy Under $30 - Insider Monkey
Citizens Initiates Coverage of Stereotaxis (STXS) with Market Outperform Recommendation - MSN
Is Stereotaxis (STXS) stock testing breakout levels | Q4 2025: EPS Tops ViewsStock Idea Sharing Hub - newser.com
Stereotaxis Inc. (STXS) reports Q4 loss, lags revenue estimates - MSN
Stereotaxis, Inc. spotlights RoboticEP system during interactive sessions at HRS2026 - Traders Union
Stereotaxis wins FDA clearance for Synchrony system, launches platform - MSN
Stereotaxis’ Catheter Earns Early Clinical Success Following FDA Approval - Diagnostic and Interventional Cardiology
Stereotaxis Stock Up on First U.S. MAGiC Procedures Post Approval - TradingView
Stereotaxis Has 1st U.S. Procedures with MAGiC Cardiac Ablation Catheter - Medical Product Outsourcing
Stereotaxis, Inc. enables first U.S. robotic arm procedures for complex CHD cases - Traders Union
Stereotaxis Announces First MAGiC Procedures in the United States - ChartMill
Lake Street Maintains Stereotaxis(STXS.US) With Buy Rating, Maintains Target Price $4 - Moomoo
After the close, Stereotaxis will break down Q1 results on May 12 - Stock Titan
Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026 - GlobeNewswire
Stereotaxis to acquire Robocath in deal aimed at expanding surgical robotics platform - Indian Pharma Post
Net current asset value per share of Stereotaxis, Inc. – LSX:A1J09L - TradingView
Stereotaxis to Acquire Robocath in Strategic 45 Million Dollar Deal - HarianBasis.co
Stereotaxis, Inc. sets sights on HRS2026 with live robotics demonstration - Traders Union
STXS to Acquire Robocath to Lead in Endovascular Robotics Market - TradingView
Stereotaxis to acquire Robocath for up to $45m - Yahoo Finance
Stereotaxis (STXS) to Acquire Robocath in Multi-Million Dollar D - GuruFocus
Stereotaxis Eyes Billions In Market Opportunity With Robocath Takeover - Benzinga
Stereotaxis to buy Robocath for up to $45M - MedTech Dive
Stereotaxis to Buy Robocath for up to $45M - Medical Product Outsourcing
Stereotaxis Inc (STXS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.05%
3.17%
자본화:
|
볼륨(24시간):